Atripla (Efavirenz/Emtricitabine/Tenofovir)

(℞) Prescription Required

Top Brand Choice
Top Generic Choice

Atripla 600mg/200mg/300mg

Product of United Kingdom
Manufactured by: Gilead Sciences, Inc.
*Product image for reference use only.
Select Quantity
Atripla 600mg/200mg/300mg
Product of United Kingdom
Manufactured by Gilead Sciences, Inc.
Top Brand Choice
Top Generic Choice

Atripla 600mg/200mg/300mg

Product of Australia
Manufactured by: Gilead Sciences, Inc.
*Product image for reference use only.
Select Quantity
Atripla 600mg/200mg/300mg
Product of Australia
Manufactured by Gilead Sciences, Inc.
Top Brand Choice
Top Generic Choice

Efavirenz/Emtricitabine... 600mg/200mg/300mg

Product of New Zealand
Manufactured by: Mylan
*Product image for reference use only.
Select Quantity
Efavirenz/Emtricitabine... 600mg/200mg/300mg
Product of New Zealand
Manufactured by Mylan
Top Brand Choice
Top Generic Choice

Atripla 600mg/200mg/300mg

Product of Canada
Manufactured by: Bristol-Myers Squibb
*Product image for reference use only.
Select Quantity
Atripla 600mg/200mg/300mg
Product of Canada
Manufactured by Bristol-Myers Squibb
Select your dosage

 

Atripla (Efavirenz/Emtricitabine/Tenofovir) Product Information

Atripla is a combination pill containing: efavirenz, emtricitabine, and tenofovir. It is used  in the treatment of HIV infection and has been combined into a single pill to simplify your treatment.

Atripla is an antiviral medication used to treat HIV. It combines Efavirenz, Emtricitabine, and Tenofovir and stops the virus from reproducing inside you.

Although it is effective in preventing the growth of HIV once contracted, it is not a cure for either HIV or AIDS. It can be taken by anyone over 12 years of age providing that they weigh 40 kilograms or more

Get Atripla Cost at a Discount with PricePro Pharmacy

The brand product is manufactured by Bristol-Myers Squibb. We offer the dose of 600mg/200mg/300mg in both brand and generic options. The brand medication starts at $1650.00 USD price for 30 tablets, and the generic tablets starts at $156.00 USD price for 30 tablets.

A brand medication is usually more expensive than a generic, because the manufacturer of the brand pays for all the research, testing and marketing. On the other hand, a generic manufacturer, can simply replicate the brand and only change the appearance of the medication. A generic may be different in shape or size, but will be therapeutically and chemically the same as the brand.

This is a prescription medication, and we will need a copy of your prescription to buy Atripla online.

The prescription can be forwarded by fax (1-855-776-0006), email ([email protected]) or by uploading an image of it to our website. If you need assistance at any point during the order process, you can contact us toll free at 1-855-776-0079  or message us on chat, which is available on our website.

Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) Medication Information

Uses

Atripla, a combination of 2 nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor, is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

Dosage

Atripla oral tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate.

Side Effects

The most common side effects of Atripla include:

  • Diarrhea
  • Nausea
  • Fatigue
  • Headache
  • Dizziness
  • Depression
  • Insomnia
  • Abnormal dreams
  • Rash 

Speak with your doctor or pharmacist for a full list of side effects that applies to you.

Precautions

Serious psychiatric symptoms: Immediate medical evaluation is recommended. 

Nervous system symptoms (NSS): NSS are frequent, usually begin 1-2 days after initiating therapy and resolve in 2-4 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset of psychiatric symptoms. 

New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine clearance before initiating treatment with ATRIPLA. In patients at risk for renal dysfunction, assess estimated creatinine clearance, serum phosphorus, urine glucose and urine protein before initiating treatment with Atripla and periodically during treatment. Avoid administering Atripla with concurrent or recent use of nephrotoxic drugs. 

Pregnancy: Fetal harm may occur when administered to a pregnant woman during the first trimester. Women should be apprised of the potential harm to the fetus. A pregnancy registry is available. 

Rash: Discontinue if severe rash develops. 

Hepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying hepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of hepatic failure, a few occurred in patients with no pre-existing hepatic disease.

Decreases in bone mineral density (BMD): Consider assessment of BMD in patients with a history of pathological fracture or other risk factors for osteoporosis or bone loss. 

Convulsions: Use caution in patients with a history of seizures. 

Immune reconstitution syndrome: May necessitate further evaluation and treatment.

Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy. 

Coadministration with other products: Do not use with drugs containing emtricitabine or tenofovir disoproxil fumarate including Complera, Emtriva, Stribild, Truvada, or Viread; or with drugs containing lamivudine. Sustiva (efavirenz) should not be coadministered with Atripla unless required for dose adjustment when coadministered with rifampin. Do not administer in combination with Hepsera.

Interactions

Some of the common drug interactions with Atripla:

  • Efavirenz
  • Didanosine
  • HIV-1 protease inhibitors

For a more complete list speak with your doctor or pharmacist 

Storage

Store at controlled room temperature (77ºF). Keep the container tightly closed. Dispense only in the original container. Do not use if the seal over the bottle opening is broken or missing. 

Pharmacist Tips

  • Atriple is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using Atripla.
  • Patients should avoid doing things that can spread HIV-1 to others.
  • The long-term effects of Atripla are unknown.
  • Redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known.

Atripla FAQs

Can I take this with food?

Atripla should be taken on an empty stomach, preferably at bedtime.

 

Can I take this if I am pregnant?

Women should avoid pregnancy while receiving Atripla and for 12 weeks after discontinuation.

 

Can I take this while breastfeeding?

Women infected with HIV should be instructed not to breastfeed.

 

What are the active ingredients in Atripla?

Efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

 

What should I avoid while taking Atripla?

Women should not become pregnant while taking Atripla and for 12 weeks after stopping it. Do not breastfeed if you are taking Atripla. Taking Atripla with alcohol or other medicines causing similar side effects as Atripla, such as drowsiness, may increase those side effects.

 

Does Atripla cure HIV-1 or AIDS?

Atripla does not cure HIV-1 infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using Atripla.

 

Related Drugs

Reference:

Atripla {package insert}. Bristol-Meyer Squibb & Gilead Sciences, LLC; 2015.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021937s037lbl.pdf

PharmD Medical Writer

Author: Dr. Larisa Roybal, PharmD

Dr. Roybal is a board-certified pharmacotherapy specialist who has practiced in both ambulatory and acute care settings. Her pharmacy interests include oncology and general inpatient pharmacy.

The above information is an educational aid only. It is not intended as medical advice for individual conditions or treatments. Talk to your doctor, nurse or pharmacist before following any medical regimen to see if it is safe and effective for you.

Back to top